Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.43 |
| ▸ | APP | P05067 | 2/20 | 0.43 |
| ▸ | BACE2 | Q9Y5Z0 | 14/20 | 0.40 |
| ▸ | CTSD | P07339 | 1/20 | 0.40 |
| ▸ | KCNH1 | O95259 | 4/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10175090 | 0.96 | BACE1 (0.45) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL19244679 | 0.96 | BACE1 (0.45) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL19266170 | 0.89 | BACE1 (0.44) | BACE1KCNH2APPBACE2KCNH1 | |
| SCHEMBL9959219 | 0.87 | BACE1 (0.43) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL10175089 | 0.87 | BACE1 (0.44) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL19244676 | 0.87 | BACE1 (0.38) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL19244678 | 0.87 | BACE1 (0.38) | BACE1KCNH2APPBACE2CTSD | |
| SCHEMBL9959340 | 0.84 | BACE1 (0.40) | BACE1APPBACE2CTSDCYP3A4 | |
| SCHEMBL9959101 | 0.83 | BACE1 (0.60) | BACE1KCNH2APPBACE2KCNH1 | |
| SCHEMBL15318254 | 0.82 | BACE1 (0.52) | BACE1KCNH2APPBACE2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9840507-B2 | 5,6-dihydro-imidazo[1,2-a]pyrazin-8-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA, NV (BE) | 2017-12-12 | — | — | US | disclosed |
| EP-2655376-B1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-23 | — | — | EP | disclosed |
| EP-2655376-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica NV (BE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-10-17 | — | — | US | disclosed |
| WO-2012085038-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274266-A1 | 5,6-DIHYDRO-IMIDAZO[1,2-a]PYRAZIN-8-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | BACE1 2/4885KCNH2 3260/4885APP 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.